The NIMML has established an extensible innovation pipeline for developing safer and more effective therapeutics for immune-mediated, infectious and chronic inflammatory diseases.
Pioneering NIMML program aimed at understanding how diet and nutritional factors influence the immune responses, thereby regulating health and disease outcomes.
The NIMML aims to comprehensively and systematically characterize mechanisms of immune dysregulation that contribute to the pathogenesis of inflammatory bowel disease (IBD), Type-1 Diabetes, psoriasis, asthma, allergies, and rheumatoid arthritis.
The NIMML combines experimental and computational methods to study the mechanisms of action underlying immune responses to H. pylori, E. coli, C. difficile, and influenza virus.
The NIMML is identifying and validating novel therapeutic targets for the treatment of type-2 diabetes and developing lead compounds that can modulate these novel targets.
Computational immunology, or immunoinformatics, has emerged as a powerful tool to quantitatively understand the dynamics of complex immunological systems.
|Katelee Averett||BREU Student|
|Hannah Bailey||BREU Student|
|Emily Baruch||BREU Student|
|Stanca Ciupe||Visiting Scholar|
|David Dachille||BREU Student|
|Xinwei Deng||Visiting Collaborator|
|Sara Elnahhas||BREU Student|
|Mary Ellen Gill||BREU Student|
|Samuel Light||USP Student|
|Callie McBride||BREU Student|
|Sara Prince||BREU Student|
|Alison Ritz||BREU Student|
|Will Sebastian||BREU Student|
|Nicole Stephens||BREU Student|
|Alison Toler||BREU Student|
|Nuria Tubau Juni||Graduate Research Assistant|
|Meghna Verma||Graduate Research Assistant|
|Sara Walters||BREU Student|
|Caroline West||Breu Student|